AOD9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Light points and Combat pages are naturally restored by one unit per turn or by raising the Emotion level of that character, which will restore all Light points. Emotion level is a mechanic that raises whenever a character wins or loses a clash, or when their dice rolls its maximum or minimum value. The group will gain an emotional level-up after their average emotion level reaches a certain point. When the emotion level rises, the player must choose one Abnormality page to apply to a librarian. Abnormality pages come in two colors, green (Awakening) and red (Breakdown), each with its own beneficial effects and drawbacks. The emotion level can rise up to five times per battle, with a total of five Abnormality pages to be picked.
=== Development of the Doctor of Psychology degree === By the 1960s, psychotherapy had become embedded within clinical psychology, but for many, the PhD educational model did not offer the necessary training for those interested in practice rather than research. There was a growing argument that said the field of psychology in the US had developed to a degree warranting explicit training in clinical practice. The concept of a practice-oriented degree was debated in 1965 and narrowly gained approval for a pilot program at the University of Illinois starting in 1968. Several other similar programs were instituted soon after, and in 1973, at the Vail Conference on Professional Training in Psychology, the practitioner–scholar model of clinical psychology—or Vail Model—resulting in the Doctor of Psychology (PsyD) degree was recognized. Although training would continue to include research skills and a scientific understanding of psychology, the intent would be to produce highly trained professionals, similar to programs in medicine, dentistry, and law. The first program explicitly based on the PsyD model was instituted at Rutgers University. Today, about half of all American graduate students in clinical psychology are enrolled in PsyD programs.
bacteria (e.g. bacteriocin, and many others) fungi (e.g. peptaibols, plectasin, and many others) cnidaria (e.g. hydramacin, aurelin) many from insects and arthropods (e.g. cecropin, attacin, melittin, mastoparan, drosomycin, thioester-containing protein 1) amphibia, frogs (magainin, dermaseptin, aurein, and others) birds (e.g. avian defensins) and mammals (e.g. cathelicidins, alpha- and beta-defensins, regIII peptides) Research has increased in recent years to develop artificially-engineered mimics of antimicrobial peptides such as SNAPPs, in part due to the prohibitive cost of producing naturally-derived AMPs. An example of this is the facially cationic peptide C18G, which was designed from the C-terminal domain of human platelet factor IV. Currently, the most widely used antimicrobial peptide is nisin; being the only FDA approved antimicrobial peptide, it is commonly used as an artificial preservative.
== Development == The vitreous fluid is not present at birth (the eye being filled with only the gel-like vitreous body), but found after age 4–5, and increases in size thereafter. Produced by cells in the non-pigmented portion of the ciliary body, the vitreous humour is derived from embryonic mesenchyme cells, which degenerate after birth. The nature and composition of the vitreous humour changes over the course of life. In adolescence, the vitreous cortex becomes more dense and vitreous tracts develop; and in adulthood, the tracts become better defined and sinuous. Central vitreous liquefies, fibrillar degeneration occurs, and the tracts break up (syneresis). Coarse strands develop with ageing. The gel volume decreases with age, and the liquid volume increases. The cortex may disappear at sites, allowing liquid vitreous to extrude adjacently into the potential space between vitreous cortex and retina (vitreous detachment).
Sources: en.wikipedia.org
Another synonymous mutation (c.3156C>T) was proposed to introduce a cryptic donor site, resulting in aberrant splicing, a theory which subsequently was confirmed in several families with ERED from different countries.
Because the spin–orbit splitting of the 7p subshell is very large in flerovium, and both of flerovium's filled orbitals in the 7th shell are stabilized relativistically; the valence electron configuration of flerovium may be considered to have a completely filled shell. Its first ionization energy of 8.539 eV (823.9 kJ/mol) should be the second-highest in group 14. The 6d electron levels are also destabilized, leading to some early speculations that they may be chemically active, though newer work suggests this is unlikely. Because the first ionization energy is higher than in silicon and germanium, though still lower than in carbon, it has been suggested that flerovium could be classed as a metalloid. Flerovium's closed-shell electron configuration means metallic bonding in metallic flerovium is weaker than in the elements before and after; so flerovium is expected to have a low boiling point, and has recently been suggested to be possibly a gaseous metal, similar to predictions for copernicium, which also has a closed-shell electron configuration. Flerovium's melting and boiling points were predicted in the 1970s to be around 70 and 150 °C, significantly lower than for the lighter group 14 elements (lead has 327 and 1749 °C), and continuing the trend of decreasing boiling points down the group. Earlier studies predicted a boiling point of ~1000 °C or 2840 °C, but this is now considered unlikely because of the expected weak metallic bonding and that group trends would expect flerovium to have low sublimation enthalpy.
Pioglitazone/metformin, sold under the brand name Actoplus Met among others, is a fixed-dose combination anti-diabetic medication used to improve glycemic control in adults with type 2 diabetes. It contains pioglitazone, a thiazolidinedione, and metformin, a biguanide.
Sources: en.wikipedia.org
The club is recorded as having played at McCracken's Paddock, Glass's Paddock, and Flemington Hill. It is likely that these are three different names for the one ground, given that McCracken's Paddock was a parcel of land that sat within the larger Glass's Paddock, which in turn was situated in an area widely known at the time as Flemington Hill. In 1882, the club moved home games to the East Melbourne Cricket Ground (since demolished) after an application to play on the Essendon Cricket Ground (later known as Windy Hill) was voted down by Lord Mayor of the City of Essendon, James Taylor, on the basis that the considered the Essendon Cricket Ground "to be suitable only for the gentleman's game of cricket". The club became known by the nickname "the Same Old Essendon" from the title and hook of the principal song performed by a band of supporters which regularly occupied a section of the grandstand at the club's games. The nickname first appeared in print in the local North Melbourne Advertiser in 1889, and ended up gaining wide use, often as the diminutive "Same Olds". This move away from Essendon, at a time when fans would walk to their local ground, didn't go down too well with many Essendon people; and, as a consequence, a new team and club was formed in 1900, unconnected with the first (although it played in the same colours), that was based at the Essendon Cricket Ground, and playing in the Victorian Football Association. It was known firstly as Essendon Town and, after 1905, as Essendon (although it was often called Essendon A, with the A standing for association).
For the crimes of rape, sodomy, and polygamy (the last removed from a later version), the punishment was to be castration for men or rhinotomy for women. For intentional maiming, the bill specified literal eye for an eye retribution. The bill never passed, due to the combination of its perceived barbarity in some parts and perceived leniency in others. In England, the Offences within the Court Act 1541 provided for cutting off a hand as punishment for striking someone inside a courtroom. Thomas Jefferson's punishments revision bill also intended to repeal this. The punishment was abolished in England and Wales by the Offences Against the Person Act 1828. As of 2021, this form of punishment is controversial, as most modern cultures consider it to be morally abhorrent, as it has the effect of permanently disabling a person and constitutes torture. It is thus seen as grossly disproportionate for crimes less than those such as murder.
The first consignment of dressed beef left the Chicago stock yards in 1857 in ordinary boxcars retrofitted with bins filled with ice. Placing meat directly against ice resulted in discoloration and affected the taste, making it impractical. During the same period, Gustavus Swift experimented by moving cut meat using a string of ten boxcars with their doors removed, and made a few test shipments to New York during the winter months over the Grand Trunk Railway (GTR). The method proved too limited to be practical. Detroit's William Davis patented a refrigerator car that employed metal racks to suspend the carcasses above a frozen mixture of ice and salt. In 1868, he sold the design to George H. Hammond, a Detroit meatpacker, who built a set of cars to transport his products to Boston, using ice from the Great Lakes for cooling. The load tended to swing to one side when the car entered a curve at high speed, and use of the units was discontinued after several derailments. In 1878, Swift hired engineer Andrew Chase to design a ventilated, well-insulated car and positioned the ice in a compartment at the top of the car, allowing the chilled air to flow naturally downward. The meat was packed tightly at the bottom of the car to keep the center of gravity low and to prevent the cargo from shifting. Chase's design proved to be a practical solution, providing temperature-controlled carriage of dressed meats. This allowed Swift and Company to ship their products across the United States and internationally.
=== Micro-mechanical cleavage === The most famous, clean and rather straightforward method of isolating graphene sheets, called micro-mechanical cleavage or more colloquially called the scotch tape method, was introduced by Novoselov et al. in 2004, which uses adhesive tape to mechanically cleave high-quality graphite crystals into successively thinner platelets. Other methods do exist like exfoliation.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.